{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2016"],"condition":["Colorectal cancer"],"disease":["Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2638141"],"location":["Japan"],"study_start_month":["8"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Phase II study of regorafenib with dose adjustment and pharmacokinetic analysis in advanced colorectal cancer","description":"Interventions: Start with regorafenib 120mg/day, and escalate the dosage to 160mg/day if compatible with the criteria at day 15\nPrimary outcome(s): Desease control rate\nStudy Design: Single arm Non-randomized","dates":{"creation":"2016-08-15"},"accession":"2638141","cross_references":{"Japan Primary Registries Network":["JPRN-UMIN000022884"]}}